Bp Plc trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 151,000 shares of the biopharmaceutical company’s stock after selling 12,000 shares during the period. Bp Plc’s holdings in Gilead Sciences were worth $10,686,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Keel Point LLC boosted its holdings in shares of Gilead Sciences by 0.4% during the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 11 shares during the last quarter. West Oak Capital LLC boosted its holdings in shares of Gilead Sciences by 0.7% during the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after purchasing an additional 32 shares during the last quarter. First Heartland Consultants Inc. boosted its holdings in shares of Gilead Sciences by 0.4% during the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after purchasing an additional 39 shares during the last quarter. Westover Capital Advisors LLC boosted its holdings in shares of Gilead Sciences by 0.8% during the 1st quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after purchasing an additional 46 shares during the last quarter. Finally, ARS Investment Partners LLC boosted its holdings in shares of Gilead Sciences by 0.9% during the 1st quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock worth $381,000 after purchasing an additional 50 shares during the last quarter. Institutional investors own 73.98% of the company’s stock.

Several research analysts have recently weighed in on GILD shares. William Blair restated an “outperform” rating on shares of Gilead Sciences in a report on Friday, June 16th. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 target price on the stock. in a report on Wednesday, June 21st. BidaskClub upgraded Gilead Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Leerink Swann restated a “market perform” rating on shares of Gilead Sciences in a report on Thursday, June 22nd. Finally, Deutsche Bank AG assumed coverage on Gilead Sciences in a report on Friday, June 23rd. They issued a “buy” rating and a $79.00 price objective on the stock. Twelve investment analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $85.66.

ILLEGAL ACTIVITY NOTICE: “Gilead Sciences, Inc. (GILD) Shares Sold by Bp Plc” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/09/gilead-sciences-inc-gild-shares-sold-by-bp-plc.html.

In related news, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the sale, the executive vice president now directly owns 106,113 shares in the company, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. Insiders have sold a total of 486,819 shares of company stock worth $39,298,919 in the last 90 days. Company insiders own 1.30% of the company’s stock.

Shares of Gilead Sciences, Inc. (GILD) opened at 82.14 on Monday. The stock has a market cap of $107.27 billion, a price-to-earnings ratio of 8.92 and a beta of 1.14. The stock’s 50 day moving average price is $80.97 and its 200-day moving average price is $71.66. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s quarterly revenue was down 8.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.08 EPS. On average, analysts predict that Gilead Sciences, Inc. will post $8.75 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were issued a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. Gilead Sciences’s payout ratio is 22.58%.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.